Stay updated on M7824 Versus Pembrolizumab in 1L PD-L1+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the M7824 Versus Pembrolizumab in 1L PD-L1+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the M7824 Versus Pembrolizumab in 1L PD-L1+ NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    3%
    Check dated 2025-06-20T03:20:44.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.2 to version 2.16.3.
    Difference
    0.3%
    Check dated 2025-06-13T00:50:29.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.3%
    Check dated 2025-06-05T20:49:50.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.
    Difference
    5%
    Check dated 2025-05-29T15:34:03.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.3%
    Check dated 2025-05-01T03:26:08.000Z thumbnail image
  6. Check
    68 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.
    Difference
    1.0%
    Check dated 2025-04-16T14:22:33.000Z thumbnail image

Stay in the know with updates to M7824 Versus Pembrolizumab in 1L PD-L1+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the M7824 Versus Pembrolizumab in 1L PD-L1+ NSCLC Clinical Trial page.